Top Page
SS Innovations International
(NASDAQ:SSII)
SS Innovations International (SSII) vs. SPDR S&P 500 ETF (SPY)
SS Innovations International Business Overview & Revenue Model
SS Innovations International Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.57M | 20.65M | 5.88M | 1.46M | 0.00 | 0.00 |
| Gross Profit | 16.20M | 8.45M | 713.45K | 489.59K | -18.79K | -37.43K |
| EBITDA | -13.12M | -17.74M | -20.26M | -5.31M | -1.47M | -1.09M |
| Net Income | -17.11M | -19.15M | -20.94M | -5.60M | -1.48M | -1.12M |
Balance Sheet | ||||||
| Total Assets | 69.58M | 42.39M | 25.48M | 6.98M | 428.61K | 317.87K |
| Cash, Cash Equivalents and Short-Term Investments | 11.71M | 466.50K | 7.03M | 217.18K | 405.77K | 160.71K |
| Total Debt | 12.68M | 18.20M | 8.22M | 8.27M | 145.00K | 195.00K |
| Total Liabilities | 29.93M | 28.93M | 11.18M | 9.66M | 287.28K | 1.19M |
| Stockholders Equity | 39.65M | 13.46M | 14.30M | -2.68M | 141.33K | -869.05K |
Cash Flow | ||||||
| Free Cash Flow | -22.35M | -10.16M | -15.81M | -1.44M | -363.03K | -94.54K |
| Operating Cash Flow | -20.29M | -9.50M | -15.36M | -5.99M | -363.03K | -90.54K |
| Investing Cash Flow | -2.07M | -661.48K | -453.33K | 240.82K | 38.15K | -44.00K |
| Financing Cash Flow | 28.20M | 9.43M | 22.80M | 5.90M | 569.95K | 266.77K |
SS Innovations International Technical Analysis
SS Innovations International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $1.35B | 19.44 | 6.60% | 2.02% | 4.69% | -51.57% | |
61 Neutral | $1.45B | -6.85 | -109.73% | ― | 17.87% | -57.03% | |
61 Neutral | $1.94B | -22.89 | -338.19% | ― | 24.76% | -10.41% | |
58 Neutral | $2.03B | -177.27 | -2.45% | ― | 9.81% | -1067.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.04B | -93.39 | -43.42% | ― | 159.43% | 67.42% | |
45 Neutral | $1.02B | -1.91 | -38.71% | ― | 4.99% | -7151.40% |
SS Innovations International Corporate Events
On January 13, 2026, SS Innovations International announced preliminary unaudited results indicating a sharp acceleration in sales of its SSi Mantra surgical robotic system for the fourth quarter and full year ended December 31, 2025. The company expects fourth-quarter 2025 revenue of about $15.0 million, an 85% increase from the prior-year period, driven by a 68% rise in SSi Mantra installations to 37 units, while full-year 2025 revenue is projected at roughly $43.0 million, up 108% year on year, with installations more than doubling to 103 units and lifting the global installed base to 168 systems. Management attributed the performance to strong demand in India and international markets and highlighted ongoing efforts to extend its footprint into the U.S. and Europe, where regulatory reviews are under way, underscoring the company’s bid to solidify its position in the growing surgical robotics market even as the figures remain preliminary and subject to final audit.
The most recent analyst rating on (SSII) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On January 6, 2026, SS Innovations announced it had completed development of five new 5-millimeter surgical instruments—spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps—for use with its SSi Mantra robotic platform, targeting procedures in pediatric, cardiac, and head and neck surgery and other operations involving smaller anatomical structures. By addressing large, underserved patient populations, particularly children in lower- and middle-income countries who currently lack access to timely, safe surgical care, these smaller instruments are intended to extend the reach of robotic surgery beyond predominantly adult use and enhance the SSi Mantra system’s competitiveness in high-precision specialties, potentially strengthening the company’s position in emerging markets and expanding its role in complex cardiac and head and neck procedures.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On November 13, 2025, Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations International, participated in an interview with Nasdaq’s Live From MarketSite. The interview was later published on December 16, 2025, and is available on both Nasdaq’s and the company’s websites. The information from the interview is considered ‘furnished’ and not ‘filed’ under the Securities Exchange Act of 1934, meaning it is not subject to the liabilities of that section.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On December 8, 2025, SS Innovations International announced the submission of a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple specialties such as general, urological, and cardiac surgeries. This strategic move aims to introduce the cost-efficient system to the U.S. market, enhancing its appeal to hospitals and surgeons, particularly in underserved communities. The company is also progressing towards obtaining a European Union CE marking certification by the first half of 2026. As of November 30, 2025, the SSi Mantra has been installed in 138 systems across eight countries, with over 7,300 surgical procedures performed, highlighting its growing global footprint.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
SS Innovations International has released an updated company presentation for November 2025, highlighting their growth and strategic plans. The company has seen significant sales growth and is expanding its global presence, with the SSi Mantra system already marketed in eight countries. The presentation underscores the company’s commitment to improving surgical robotics technology and its potential impact on the healthcare industry.
The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On November 6, 2025, SS Innovations International announced the successful completion of the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC). This compact and portable console allows telesurgeries to be performed from various locations, including physician offices, without the need for a full operating room. The milestone surgery was conducted by Dr. Sudhir Srivastava from New Delhi, India, on a patient in Jaipur, India, highlighting the TSC’s ability to extend surgical expertise remotely. This development is expected to enhance patient access to surgical care and provide hospital networks with greater flexibility.
The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On October 28, 2025, SS Innovations International announced its third-quarter financial results, reporting a 192.5% increase in revenue to $12.8 million, driven by higher sales of the SSi Mantra 3 unit. Despite a net loss of $3.7 million, the company saw significant growth in installations and surgeries, with a 350% increase in SSi Mantra installations compared to the previous year. The company is progressing towards regulatory milestones, including a 510(k) submission to the FDA and a European Union CE marking certification, indicating robust growth prospects.
The most recent analyst rating on (SSII) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
On October 21, 2025, SS Innovations International announced that its executives, Dr. Sudhir Srivastava and Dr. Vishwa Srivastava, will participate in upcoming investor conferences, including the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025. These events will provide opportunities for one-on-one and small group meetings, and a live webcast of the Stifel presentation will be available on the company’s website. This participation underscores the company’s commitment to engaging with investors and stakeholders, potentially enhancing its industry positioning and visibility.
The most recent analyst rating on (SSII) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
SS Innovations International has released an updated company presentation for October 2025, highlighting its growth and strategic plans. The company has seen significant expansion, with 125 SSi Mantra systems installed and over 6,000 surgeries performed across nine specialties. The presentation underscores the company’s commitment to global expansion, particularly into Europe and the United States, and its strategy for long-term sustainable growth. The leadership team, with a proven track record in surgical robotics, aims to leverage favorable industry trends and a growing market to enhance its positioning and deliver advanced surgical solutions.
The most recent analyst rating on (SSII) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.